Mount Sinai Tisch Cancer Center

Check out our robust portfolio of cancer clinical trials at oncore-search.mssm.edu/index

. @TischCancer and @CancerHopeNet launch peer support program to help patients navigate treatment, survivorship, and clinical trials cancerletter.com/in-brief/20260…

We look forward to a presentation by @DmitriyZamarin on May 26: "The Wiring of Immune Resistance: Heterogeneity Circuits in #OvarianCancer" @IcahnMountSinai

We look forward to a special presentation by Michael Andreeff, MD, PhD, @UTMDAnderson, on May 21.

Congratulations to Diego Chowell, PhD, on receiving the NSF CAREER Award, the National Science Foundation’s highest honor for early-career faculty. Dr. Chowell’s research will develop AI-driven protein language models to better understand immune recognition, advancing innovative approaches at the intersection of immunology and computational biology. Read more about the Chowell Lab here: mshs.co/4tK2y6g

onclive.com/view/data-make… Suchitra Sundaram, MD, @IcahnMountSinai, discusses treatment options in CLL.

PARP inhibitor–associated folate deficiency anemia ashpublications.org/bloodrci/artic… @IcahnMountSinai

Long term outcomes of idasanutlin therapy in hydroxyurea-refractory polycythemia vera patients pubmed.ncbi.nlm.nih.gov/42148701/ John Mascarenhas, Ronald Hoffman and colleagues @IcahnMountSinai

mountsinai.org/about/newsroom… “Our findings show that mezigdomide can reinvigorate exhausted T cells and enhance the activity of immunotherapies that are already changing the standard of care for multiple myeloma,” said Samir Parekh @IcahnMountSinai #MultipleMyeloma

Ikaros degradation by mezigdomide reduces T-cell dysfunction and improves the efficacy of antimyeloma T-cell therapies ashpublications.org/blood/article/… Samir Parekh and colleagues #MultipleMyeloma

The Mount Sinai Tisch Cancer Center and Cancer Hope Network have launched Peer Access to Trials, Hope and Support (PATHS), a new peer-to-peer mentorship program designed to support patients and caregivers navigating cancer treatment, survivorship, and clinical trials. Through the program, patients and families will be connected one-on-one with trained peer mentors who have faced cancer themselves, offering guidance, understanding, and support from lived experience. “Clinical trials are critical to advancing cancer care, but too often patients feel unsure or hesitant about participating,” said Karyn Goodman, MD, MS. “Peer support can play a powerful role in giving patients the confidence, perspective, and information they need to make informed decisions about their treatment options.” The PATHS program expands access to emotional and practical support while helping patients better understand the role of clinical trials in cancer care. The inaugural group of peer mentors is currently being trained and will join a national network of volunteers supporting patients through every stage of their journey. Learn more about the PATHS program and cancer support services at Mount Sinai: mshs.co/3Rji9Mv

.@ddorshow, @IcahnMountSinai, guides conversation about institutional culture, leadership philosophy, and scientific ambition that shaped @StJude.

Congratulations to our postdoc @cris_megino for winning the #ArtOfTheBrain image contest at the @SinaiBrain 18th Annual Neuroscience Retreat with this beautiful image. 🧠✨ 🏆 1st Place – Best Image Contest ❤️ 2nd Place – Most “Liked” Social Media Image @TischCancer @CoRESinai

PARP4 ADP-ribosylates PIDD1 to complete a phospho/SUMO/PAR-ylation cascade that orchestrates PIDDosome assembly | Science Advances science.org/doi/10.1126/sc… Samuel Sidi, PhD, @IcahnMountSinai, and colleagues

Evaluating EV plus pembrolizumab in muscle-invasive #BladderCancer: #KEYNOTEB15 results. @MattGalsky @TischCancer joins @ERPlimackMD @FoxChaseCancer to discuss this phase III trial randomizing 808 #MIBC patients to neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab versus gemcitabine-cisplatin. #WatchNow > bit.ly/4lGfZBP

.@Veracyte secures Medicare coverage for TrueMRD monitoring test in muscle-invasive #bladdercancer investor.veracyte.com/news-releases/… Matthew Galsky, MD, @IcahnMountSinai, weighs in.

Our recent @CellCellPress study with @ChrisAWalsh1 lab on somatic mutations in microglia of AD brains highlighted in @NatureAging nature.com/articles/s4358…

ajmc.com/view/clinical-… @DDoroshow @IcahnMountSinai #clinicaltrials

We are excited about our new Peer Support Program with #CancerHopeNetwork to help patients navigate treatment, clinical trials, and more. mountsinai.org/about/newsroom… #CancerCare #PeerSupport

powerfulpatients.org/resource/lung-… Thomas Marron, MD, PhD, @IcahnMountSinai, shares tips for careful monitoring. #LungCancer